Anti-Mouse Galectin-9 Antibody (RG9-1) 

Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4⁺ and CD8⁺ T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia^[1][2][3][4].

Rat IgG2b kappa

Rat IgG2b kappa, Isotype Control

Mouse

Anti-Mouse Galectin-9 Antibody (RG9-1) (10 μg, 2 h) significantly increases the killing effect of allogeneic reactive T cells on corneal endothelial cells (CECs) and inhibits the apoptosis of allogeneic reactive CD4⁺ T cells^[1].
Anti-Mouse Galectin-9 Antibody (RG9-1) (20 μg/mL) significantly increases the production of IFN-γ in splenic T cells stimulated by Concanavalin A (HY-P2149)^[2].
Anti-Mouse Galectin-9 Antibody (RG9-1) (20 μg/mL) significantly increases the secretion of TNF-α and IL-6 in the co-culture system of macrophages and T cells^[2].
Anti-Mouse Galectin-9 Antibody (RG9-1) can block Gal-9/TIM-3 interaction and reduce Jurkat T cell apoptosis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse Galectin-9 Antibody (RG9-1) (0.2 mg, i.p., 3 times a week, for 8 weeks) significantly shortens the survival time of transplants in male BALB/c mice with a corneal transplantation model^[1].
Anti-Mouse Galectin-9 Antibody (RG9-1) (100 μg, i.p., once every 3 days, for 3 times) significantly enhances anti-tumor efficacy and prolongs survival combined with GITR mAb (HY-P990124) in female C57BL/6J mice bearing MC-38 tumors and BALB/c mice bearing EMT-6 tumors^[3].
Anti-Mouse Galectin-9 Antibody (RG9-1) (6 mg/kg, i.p., 3 times every weeks, for 7 weeks) significantly delays the progression of leukemia in female C57BL/6 mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

16859  [NCBI]

O08573-2

in vivo Galectin-9 blockade; in vitro Galectin-9 blockade

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Mouse Galectin-9 Antibody (RG9-1)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shimmura-Tomita M, et al. Galectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts. PLoS One. 2013 May 7;8(5):e63620.  [Content Brief]

  [2]. Uchida Y, et al. T-cell immunoglobulin mucin-3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4-dependent manner. Gastroenterology. 2010 Dec;139(6):2195-206.  [Content Brief]

  [3]. Yang R, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021 Feb 5;12(1):832.  [Content Brief]

  [4]. Llaó-Cid L, et al. Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target. Nat Commun. 2025 Aug 7;16(1):7271.  [Content Brief]